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Figure 1. Distribution of Candida albicans and non-albicans species of Candida (C. non-albicans)
before and after the study.
the epigastrium. Blood tests revealed leu-
kocytosis (WBC count, cells/L,98.29 10
with 78.2% polymorphonuclear leuko-
cytes) and an elevated C-reactive protein
level (6.47 mg/dL). The biliary enzyme
levels were within the normal limits (al-
kaline phosphatase, 226 U/L; g-glutamyl
transpeptidase, 203 U/L). Urinary tract in-
fection was the tentative diagnosis, and
treatment with cephalosporin and genta-
micin was started.
Abdominal ultrasonography revealed a
lobulated, hypoechoic, cystic lesion in the
lateral segment of the left hepatic lobe. The
abdominal CT showed a 5-cm heteroge-
neous, septated, nodular lesion with mar-
ginal enhancement, a finding compatible
with pyogenic liver abscess. However, a
linear radiopaque density within the lesion
was also noted (figure 1 top, arrow). The
antibiotic therapy was changed to cefo-
tiam and metronidazole. The fever became
low-grade, and the antibiotic therapy was
changed to ampicillin-sulbactam because
of a decreased hemoglobin level, platelet
count, and WBC count, which were prob-
ably adverse effects of cephalosporin
therapy.
The patient became afebrile after 7 days
of intravenous antibiotic therapy. Culture
of a specimen from percutaneous tran-
shepatic abscess aspiration revealed Kleb-
siella pneumoniae and aerobic, gram-pos-
itive bacilli. In accordance with the
findings of the drug susceptibility test, the
course of antibiotics was changed to
amoxicillin-clavulanate. After 15 days of
hospitalization, the patient was discharged
in a stable condition. During the following
2 years, no associated symptoms or signs
recurred. A CT scan performed at a fol-
low-up visit at 2 years showed that the
foreign body remained in the left liver but
there was no adjacent inflammation (fig-
ure 1, bottom).
At least 10 cases of hepatic abscess due
to an ingested fish bone have been re-
ported [1–5]. Treatments included drain-
age of the abscess, removal of the foreign
body, and administration of appropriate
antibiotics. All reported cases were treated
with either percutaneous transhepatic re-
moval or surgical removal of the fish bone.
If there is a strong suspicion of bowel per-
foration by a foreign body or if a foreign
body is detected preoperatively, surgery is
considered the treatment of choice in cur-
rent clinical practice [6, 7]. To the best of
our knowledge, this is the first docu-
mented case of a hepatic abscess secondary
to fish bone penetration that was success-
fully treated without removal of the for-
eign body. We thus recommend that med-
ical approaches could be attempted first
in such cases, especially when contrain-
dications for surgery exist.
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Fluconazole Prophylaxis for
Critically Ill Patients at High
Risk for Candida Infection
Sir—I have read with interest the article
by Wenzel and Gennings [1] recently pub-
lished in a supplement of the journal. In
this article, the authors comment on the
strategy followed at the Johns Hopkins
University Hospital for patients in critical
care units who are at particularly high risk
for Candida infection, which is to give
prophylactic anti-Candida antibiotics to
all patients expected to be in an intensive
care unit for 3 days. This strategy has
been shown to reduce the overall rate of
candidal infections in a study that ex-
amined all anatomic sites, but it did not
reduce mortality in a surgical intensive
care unit at Johns Hopkins University
Hospital [2]. However, only 1 patient re-
ceiving fluconazole developed a candidal
bloodstream infection, and 2 patients re-
ceiving placebo developed infection of the
blood and the peritoneum [1].
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In a study conducted in our institution
that invovled critically ill patients at high
risk for development of candidal infec-
tions, patients were randomly assigned to
receive fluconazole at a dosage of 100 mg
daily ( ) or placebo ( ) [3].np 103 np 101
Candidal infections occurred less fre-
quently in the fluconazole group than in
the placebo group (5.8% vs. 16% of pa-
tients; rate ratio, 0.35; 95% CI, 0.11–0.94).
Approximately 90% of candidemia epi-
sodes occurred in the placebo group (rate
ratio for fluconazole use, 0.10; 95% CI,
0.02–0.74). The crude mortality rate in
both groups was similar. In conclusion,
our results demonstrate that, for selected
critically ill patients at high risk, flucon-
azole prophylaxis decreases the incidence
of candidal infection, and of candidemia,
in particular.
We did not observe changes in the pat-
terns of distribution of infection due to
Candida albicans and infection due to
non-albicans species of Candida when we
compared the species distribution before
and after the study [4] (figure 1). Nev-
ertheless, we would recommend close sur-
veillance for the emergence of antifungal
resistance.
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